Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $29,658.24 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,878 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $29,658.24. Following the sale, the insider now owns 158,687 shares in the company, valued at approximately $964,816.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sight Sciences Stock Performance

SGHT stock opened at $5.81 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.01 and a quick ratio of 10.50. Sight Sciences, Inc. has a 1 year low of $1.04 and a 1 year high of $8.45. The company has a market cap of $289.08 million, a P/E ratio of -5.19 and a beta of 2.71. The stock’s fifty day moving average price is $6.50 and its 200-day moving average price is $6.23.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. The business had revenue of $21.37 million for the quarter, compared to analysts’ expectations of $21.32 million. During the same period last year, the firm posted ($0.30) earnings per share. On average, equities analysts forecast that Sight Sciences, Inc. will post -1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SGHT. Morgan Stanley upped their price objective on Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, August 2nd. Lake Street Capital started coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Citigroup upped their target price on shares of Sight Sciences from $6.00 to $6.50 and gave the company a “neutral” rating in a research note on Wednesday, July 10th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.25.

Institutional Trading of Sight Sciences

Several large investors have recently added to or reduced their stakes in SGHT. Vanguard Group Inc. raised its position in Sight Sciences by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares during the period. Long Focus Capital Management LLC raised its holdings in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after purchasing an additional 260,594 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Sight Sciences by 25.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after purchasing an additional 76,549 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Sight Sciences during the second quarter valued at $1,234,000. Finally, RTW Investments LP bought a new stake in Sight Sciences during the fourth quarter valued at about $850,000. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.